Rapid, Non-invasive, Regional Functional Imaging of the Retina. (Diabetic Retinopathy Diagnosis Device)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01546766|
Recruitment Status : Recruiting
First Posted : March 7, 2012
Last Update Posted : November 17, 2016
|Condition or disease||Intervention/treatment|
|Diabetes Retinal Disorders||Device: Pupillometry testing.|
This study consists of three parts. The first part is to work with a limited number of normal individuals and those with known diabetic retinopathy to test a variety of the light conditions to find those that appear to be optimal for detecting retinal damage. The second part of this study, which is to test the instrument and these conditions with both normal subjects and a series of diabetics with varying degrees of severity of diabetic retinopathy. This part of the study is intended to determine how sensitive and specific the detection method is over the full range of retinal damage that is observed in diabetics. The third part of this study is to use the same instrument either with the same testing conditions as used for the diabetics or with modifications based on the regional areas of the retina that are damaged for other conditions, including (but not limited to) sickle cell retinopathy, retinitis pigmentosa, vascular diseases of the retina.
The risks from this study are minimal. All of the portions of the study that are required for the clinical assessment of the participant's retinal health are consistent with the standard of care for their condition. For diabetics with no clinically evident retinal damage from diabetes, they will receive a regular dilated eye exam and photographs to document the appearance of their retina. For those with more severe diabetic changes, special retinal photographs and fluorescein angiography (photographs taken in the presence of a dye that is injected into an arm vein that allows one to study the detailed changes of the blood vessels in the retina) will be done to more accurately assess the degree of diabetic damage.
The long-term objective of this application is to develop an imaging device for the early detection, diagnosis and quantification of the degree of midperipheral retinal ischemia in Diabetic Retinopathy (DR). Earlier diagnosis of DR could facilitate intervention at a stage that may prevent or lessen permanent damage from the ravages of the disease, in turn, improving patient quality of life and reducing lifetime treatment costs. DR is one of the more debilitating potential outcomes of diabetes posing a major threat to the quality of life of diabetics. Experts believe that DR is the leading cause of blindness in the industrialized world in people between the ages of 25 and 74 years old.
The American Academy of Ophthalmology states that DR is the leading cause of blindness among working Americans and currently affects nearly seven million people in the U.S. Early detection can help treat DR and salvage about 90 percent of vision loss, but about one-third of the diabetic population remains undiagnosed, translating into approximately 5.7 million people in the U.S. Delay in the primary diagnosis of diabetes allows diabetic complications to progress significantly before detection further increasing the risks associated with the disease by making the treatment much more complicated. Diabetes management guidelines advocate initiation of therapeutic intervention early in the prognosis of the disease. Estimates of diabetics in the U.S. with DR range from 15% to as high as 40%.
|Study Type :||Observational|
|Estimated Enrollment :||315 participants|
|Observational Model:||Case Control|
|Official Title:||Developing a Non-invasive Method and Device for Assessing the Degree of Midperipheral Retinal Ischemia in Diabetic Retinopathy.|
|Study Start Date :||February 2007|
|Estimated Primary Completion Date :||July 2017|
|Estimated Study Completion Date :||July 2017|
Subjects with diabetes
(Subjects that have been diagnosed with diabetes).
|Device: Pupillometry testing.|
(Subjects with no history of ocular problems).
|Device: Pupillometry testing.|
Subjects with retinal conditions
(Subjects with a history of retinal disorders except diabetes).
|Device: Pupillometry testing.|
- Pupillary response [ Time Frame: 3 months ]
We will analyze the following three components of the pupillary response: latency, constriction velocity and amplitude. The measurements will be taken after initiation of the light stimulus.
These functions will be determined for each eye of each subject using both the central and annular stimuli. Each set of experimental conditions will yield a unique relative luminance ratio that can be used to compare the relative functional integrity of the peripheral retina with respect to the central macula.
- Pupillary response. [ Time Frame: 1 year ]
Constriction velocity, latency and amplitude will allow us to compare the sensitivity of the testing methods with a variety of diabetic cases so that we can establish the most appropriate method for generalized screening.
The secondary measures will include the differences in maximal constriction and the pupil diameters at the time of maximal rate of constriction as well as analyses of the impact of the light stimuli on the three latency measures of response.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01546766
|Contact: Michael B. Gorin, MD, PhD||1 (310) email@example.com|
|Contact: Maria Carolina Ortube, MD||1 (310) firstname.lastname@example.org|
|United States, California|
|Jules Stein Eye Institute, Dept. of Ophthalmology, David Geffen School of Medicine at UCLA||Recruiting|
|Los Angeles, California, United States, 90095|
|Contact: Michael B. Gorin, MD, PhD 310-794-5400 email@example.com|
|Contact: Maria Carolina Ortube, MD 1 (310) 794-5598 firstname.lastname@example.org|
|Principal Investigator: Michael B. Gorin, MD, PhD|
|Sub-Investigator: Maria Carolina Ortube, MD|
|Sub-Investigator: Steve Nusinowitz, PhD|
|United States, Pennsylvania|
|Neuro Kinetics Inc.||Recruiting|
|Pittsburgh, Pennsylvania, United States, 15238|
|Contact: Alexander Kiderman, PhD 412-963-6649 email@example.com|
|Principal Investigator:||Michael B. Gorin, MD, PhD||Jules Stein Eye Institute, Dept. of Ophthalmology, David Geffen School of Medicine at UCLA|
|Study Director:||Alexander Kiderman, PhD||Neuro Kinetics, Inc.|